CPA
TARS icon

Capital Performance Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Capital Performance Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$164 – 2402
2024
Q3 		$164 Buy
+5
New +$141 ﹤0.01% 2603

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Capital Performance Advisors's TARS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 5 shares — an estimated $164 sold.

Capital Performance Advisors first reported a position in TARS in Q3 2024 and held it in 1 quarter. The position peaked at $164 in Q3 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $164.
  • Capital Performance Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Tarsus Pharmaceuticals position peaked at $164 in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.